Low-dose vigabatrin (gamma-vinyl GABA)-induced damage in the immature rat brain

Experimental Neurology
R S SidhuS S Seshia

Abstract

The antiepileptic drug, vigabatrin, inhibits GABA transaminase, thus elevating GABA levels in the brain. In adult animal experiments, high-dose (200 mg/kg/day) chronic vigabatrin administration is associated with potentially reversible myelin vacuolation, a phenomenon not documented in humans. We hypothesized that vigabatrin might adversely affect myelination in the developing brain. Rats were given vigabatrin in doses comparable to those used clinically (15-50 mg/kg/day), from age 12 to 16 days. The rats were killed at age 19-20 days. We observed decreased myelin staining in the external capsule, axonal degeneration in white matter, evidence of glial cell death in the white matter, and reactive astrogliosis in the frontal cortex. We did not detect myelin vacuolation. These findings indicate that vigabatrin can have adverse and potentially irreversible effects on the developing rat brain. The mechanism of damage could be direct toxicity of vigabatrin or an indirect effect mediated through elevated GABA levels. Vigabatrin has been recommended as a treatment for some forms of childhood epilepsy; therefore, further studies are needed to assess the risks in children.

References

Jan 1, 1990·Developmental Neuroscience·S M LeVineW B Macklin
Jan 1, 1990·Toxicologic Pathology·J P GibsonJ W Newberne
Sep 1, 1989·The Journal of Physiology·Y Ben-AriJ L Gaiarsa
Jan 1, 1989·British Journal of Clinical Pharmacology·J J HauwC Duyckaerts
Jan 1, 1989·British Journal of Clinical Pharmacology·L I PerssonM Nilsson
Jan 1, 1989·Epilepsia·W H Butler
Jan 1, 1989·Epilepsia·P J RiekkinenT Halonen
Jun 1, 1989·Canadian Journal of Physiology and Pharmacology·S Liske, M E Morris
Apr 1, 1988·Journal of Neurocytology·M B Graeber, G W Kreutzberg
May 1, 1987·Journal of Neuropathology and Experimental Neurology·B A BrodyF H Gilles
Sep 21, 1984·Science·W M CowanB B Stanfield
Oct 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·A GuidottiE Costa
Oct 1, 1994·Neurology·K L WeissJ C Arezzo
Sep 1, 1993·Toxicologic Pathology·J T YarringtonR J Marler
Mar 19, 1993·Brain Research. Developmental Brain Research·J Y LimJ D Kocsis
Jan 1, 1993·Neuroscience and Biobehavioral Reviews·P J MorganeJ R Galler
Oct 1, 1995·Neuropediatrics·P UldallH Høgenhaven
Jan 1, 1995·Pharmacology & Therapeutics·R E Appleton

❮ Previous
Next ❯

Citations

Sep 24, 2009·Journal of Child Neurology·Myles HortonMarc R Del Bigio
Mar 26, 2005·Current Opinion in Neurology·Raili Riikonen
Jun 23, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·S J Spence, R Sankar
May 23, 2000·Journal of Neurochemistry·K Lukasiuk, A Pitkänen
Oct 20, 2006·Neuroscience·R Káradóttir, D Attwell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Brain developing: Influences & Outcomes

This feed focuses on influences that affect the developing brain including genetics, fetal development, prenatal care, and gene-environment interactions. Here is the latest research in this field.

Related Papers

Journal of Neurology, Neurosurgery, and Psychiatry
H A RingE H Reynolds
Drug Metabolism and Drug Interactions
Müjgan CengizMehmet Seven
Pharmacology & Toxicology
A Sabers, L Gram
Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
Dawna Duncan Armstrong
© 2021 Meta ULC. All rights reserved